dipyridamole has been researched along with Anti-Phospholipid Antibody Syndrome in 5 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate whether antiplatelet agents, dilazep and dipyridamole, inhibit tissue factor (TF) expression on monocytes induced by IgG from patients with antiphospholipid syndrome (APS)." | 7.72 | Dilazep and dipyridamole inhibit tissue factor expression on monocytes induced by IgG from patients with antiphospholipid syndrome. ( Zhou, H, 2004) |
| "To investigate whether antiplatelet agents, dilazep and dipyridamole, inhibit tissue factor (TF) expression on monocytes induced by IgG from patients with antiphospholipid syndrome (APS)." | 3.72 | Dilazep and dipyridamole inhibit tissue factor expression on monocytes induced by IgG from patients with antiphospholipid syndrome. ( Zhou, H, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ali, RA | 1 |
| Gandhi, AA | 1 |
| Meng, H | 1 |
| Yalavarthi, S | 1 |
| Vreede, AP | 1 |
| Estes, SK | 1 |
| Palmer, OR | 1 |
| Bockenstedt, PL | 1 |
| Pinsky, DJ | 1 |
| Greve, JM | 1 |
| Diaz, JA | 1 |
| Kanthi, Y | 1 |
| Knight, JS | 1 |
| Zhou, H | 1 |
| Menashe, Y | 1 |
| Ben-Baruch, G | 1 |
| Greenspoon, JS | 1 |
| Carp, HJ | 1 |
| Rosen, DJ | 1 |
| Mashiach, S | 1 |
| Many, A | 1 |
| Brady, L | 1 |
| Magilavy, D | 1 |
| Black, DD | 1 |
| Monastiri, K | 1 |
| Chaieb, A | 1 |
| Skouri, H | 1 |
| Slama, A | 1 |
| Chebil, S | 1 |
| Maaroufi, R | 1 |
| Nouira, M | 1 |
| Mokni, M | 1 |
| Zanina, R | 1 |
| Saidi, H | 1 |
| Ben Amor, F | 1 |
| Bibi, M | 1 |
| Mahjoub, T | 1 |
| Kortas, M | 1 |
| Snoussi, N | 1 |
| Khairi, H | 1 |
5 other studies available for dipyridamole and Anti-Phospholipid Antibody Syndrome
| Article | Year |
|---|---|
Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Animals; Antibodies, Antiphospholipid; Antiphospholipid S | 2019 |
Dilazep and dipyridamole inhibit tissue factor expression on monocytes induced by IgG from patients with antiphospholipid syndrome.
Topics: Adrenergic Antagonists; Antiphospholipid Syndrome; Cell Separation; Dilazep; Dipyridamole; Gene Expr | 2004 |
Successful pregnancy outcome with combination therapy in women with the antiphospholipid antibody syndrome.
Topics: Adult; Antiphospholipid Syndrome; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Heparin; | 1993 |
Portal vein thrombosis associated with antiphospholipid antibodies in a child.
Topics: Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Child, Preschool; Dipyridamole; Esophageal a | 1996 |
[Primary antiphospholipid syndrome in obstetrics. Apropos of 4 cases with fetal survival].
Topics: Adult; Anti-Inflammatory Agents; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Dipyridamole; D | 1996 |